Skip to Content

Cell therapy improves progression-free survival with 50% in advanced melanoma

At ESMO 2022, the first randomized phase 3 trial to investigate T-cell therapy in solid advanced tumors in patients with advanced melanoma is presented. Results suggest that treatment with tumor-infiltrating lymphocytes (TIL) significantly improves progression-free survival when compared to ipilimumab (IPI). Get the full presentation from Professor John Haanen in this MEDtalk.

John Haanen

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top